Analytical Data
-
Gene name
POLg1
- Application
-
Alternative Names
POLg1；MDP1；POLG1；POLGA；DNA polymerase subunit gamma-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P54098
-
Expression Region
2-1239aa
-
AA Sequence
MHHHHHHDYKDDDDKSRLLWRKVAGATVGPGPVPAPGRWVSSSVPASDPS DGQRR RQQQQQQQQQQQQQPQQPQVLSSEGGQLRHNPLDIQMLSRGLH EQIFGQGGEMP GEAAVRRSVEHLQKHGLWGQPAVPLPDVELRLPPLYG DNLDQHFRLLAQKQSLPYL EAANLLLQAQLPPKPPAWAWAEGWTRYGP EGEAVPVAIPEERALVFDVEVCLAEGT CPTLAVAISPSAWYSWCSQRL VEERYSWTSQLSPADLIPLEVPTGASSPTQRDWQEQ LVVGHNVSFDRA HIREQYLIQGSRMRFLDTMSMHMAISGLSSFQRSLWIAAKQGKHK VQP PTKQGQKSQRKARRGPAISSWDWLDISSVNSLAEVHRLYVGGPPLEKEPR ELFV KGTMKDIRENFQDLMQYCAQDVWATHEVFQQQLPLFLERCPHPV TLAGMLEMGVSY LPVNQNWERYLAEAQGTYEELQREMKKSLMDLANDA CQLLSGERYKEDPWLWDLE WDLQEFKQKKAKKVKKEPATASKLPIEGA GAPGDPMDQEDLGPCSEEEEFQQDVM ARACLQKLKGTTELLPKRPQHL PGHPGWYRKLCPRLDDPAWTPGPSLLSLQMRVTP KLMALTWDGFPLHY SERHGWGYLVPGRRDNLAKLPTGTTLESAGVVCPYRAIESLYR KHCLE QGKQQLMPQEAGLAEEFLLTDNSAIWQTVEELDYLEVEAEAKMENLRAAV P GQPLALTARGGPKDTQPSYHHGNGPYNDVDIPGCWFFKLPHKDGNSC NVGSPFAKD FLPKMEDGTLQAGPGGASGPRALEINKMISFWRNAHKRI SSQMVVWLPRSALPRAVI RHPDYDEEGLYGAILPQVVTAGTITRRAVE PTWLTASNARPDRVGSELKAMVQAPPG YTLVGADVDSQELWIAAVLGD AHFAGMHGCTAFGWMTLQGRKSRGTDLHSKTATTV GISREHAKIFNYG RIYGAGQPFAERLLMQFNHRLTQQEAAEKAQQMYAATKGLRWY RLSDE GEWLVRELNLPVDRTEGGWISLQDLRKVQRETARKSQWKKWEVVAERAWK GGTESEMFNKLESIATSDIPRTPVLGCCISRALEPSAVQEEFMTSRVN WVVQSSAVDY LHLMLVAMKWLFEEFAIDGRFCISIHDEVRYLVREEDR YRAALALQITNLLTRCMFAYK LGLNDLPQSVAFFSAVDIDRCLRKEVT MDCKTPSNPTGMERRYGIPQGEALDIYQIIEL TKGSLEKRSQPGP
-
Molecular Weight
141 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
POLg1, the catalytic subunit of mitochondrial DNA polymerase gamma, plays a crucial role in mitochondrial DNA replication and repair. Mitochondria are essential organelles involved in energy production, and their dysfunction is associated with a variety of diseases, including neurodegenerative disorders, metabolic syndromes, and aging-related conditions. The importance of POLg1 has been underscored by its involvement in mitochondrial genome maintenance; mutations in the POLg1 gene can lead to mitochondrial diseases characterized by muscle weakness, neurological dysfunction, and multisystem failures. Research into POLg1 has gained momentum due to its potential as a therapeutic target for these conditions. Scientists aim to understand the enzyme's structure, function, and interaction with other mitochondrial proteins to develop targeted interventions. Given that mitochondrial dysfunction is a common hallmark of various diseases, elucidating the mechanisms governing POLg1 activity may pave the way for novel strategies in precision medicine, emphasizing the urgency of comprehensively investigating this critical enzyme in both health and disease contexts. This research not only enhances our understanding of mitochondrial biology but also holds promise for innovative treatments that could mitigate the impact of mitochondrial-related pathologies.
